RU-22930 explained

RU-22930 is a nonsteroidal antiandrogen (NSAA) related to the NSAAs flutamide and nilutamide (RU-23908) and was developed by Roussel Uclaf but was never marketed.[1] [2] It is a selective antagonist of the androgen receptor and consequently has progonadotropic effects by increasing gonadotropin and testosterone levels via disinhibition of the hypothalamic-pituitary-gonadal axis. Unlike flutamide and nilutamide, the drug is said to be short-acting and inactive by injection, but it has been found to be active topically in animals, and hence could be useful for the treatment of androgen-dependent skin conditions.[3]

See also

Notes and References

  1. Tindall DJ, Chang CH, Lobl TJ, Cunningham GR . Androgen antagonists in androgen target tissues . Pharmacol. Ther. . 24 . 3 . 367–400 . 1984 . 6205409 . 10.1016/0163-7258(84)90010-x.
  2. Singh SM, Gauthier S, Labrie F . Androgen receptor antagonists (antiandrogens): structure-activity relationships . Curr. Med. Chem. . 7 . 2 . 211–47 . 2000 . 10637363 . 10.2174/0929867003375371.
  3. Book: Thomson. D. S.. Pharmacology of the Skin II. Pharmacology of Anti-androgens in the Skin. Handbook of Experimental Pharmacology. 87 / 2. 1989. 483–493. 0171-2004. 10.1007/978-3-642-74054-1_36. 978-3-642-74056-5.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "RU-22930".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.